| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, Mayo Clinic, Rochester, MN.
Address correspondence and reprint requests to Dr. Gregory D. Cascino, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Objective: To determine the incidence, risk factors, and long-term sequelae of the purple glove syndrome (PGS) in hospital patients receiving IV phenytoin.
Background: PGS is a poorly understood, potentially serious local complication of IV phenytoin administration characterized by progressive distal limb edema, discoloration, and pain.
Methods: The pharmacologic records of the Mayo Foundation hospitals were reviewed to identify 179 consecutive patients who had IV phenytoin ordered during a 3-month period. Their hospital records were then reviewed to confirm IV phenytoin treatment, the frequency of PGS (defined as the progressive development of edema, discoloration, and pain in the limb after administration of IV phenytoin), and the outcome of PGS.
Results: A total of 152 patients received IV phenytoin, and nine (5.9%) developed PGS. PGS patients received a greater median initial dose of phenytoin, total 24-hour dose, and total number of doses (all p < 0.05). In addition, the median age of the PGS patients was older, their infusion was more often given for acute seizures, it was less likely to be administered in the operating room, and the length of their hospital stay was longer (all p < 0.05). One patient required surgical therapy, and all other patients resolved within 3 weeks with conservative management.
Conclusions: PGS is not rare and elderly patients and individuals receiving large, multiple doses are particularly at risk. This iatrogenic complication may be preventable by substituting fosphenytoin for IV phenytoin.
Received March 16, 1998. Accepted in final form June 27, 1998.
This article has been cited by other articles:
|
|
 |
|
  C. A. Twardowschy, L. De Paola, F.M.B. Germiniani, L. C. Werneck, and C. Silvado Pearls & Oy-sters: Soft-tissue necrosis as a result of intravenous leakage of phenytoin Neurology, November 10, 2009; 73(19): e94 - e95. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Rosenow and S. Knake Review: Recent and future advances in the treatment of status epilepticus Therapeutic Advances in Neurological Disorders, July 1, 2008; 1(1): 25 - 32. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Seth, D. Chester, and N. Moiemen A review of chemical burns Trauma, April 1, 2007; 9(2): 81 - 94. [Abstract] [PDF]
|
|
|
|
 |
|
 S. S. Chung, N. C. Wang, and D. M. Treiman Comparative Efficacy and Safety of Antiepileptic Drugs for the Treatment of Status Epilepticus Journal of Pharmacy Practice, April 1, 2007; 20(2): 137 - 146. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Chokshi, J. Openshaw, N. N Mehta, and E. Mohler III Purple glove syndrome following intravenous phenytoin administration Vascular Medicine, February 1, 2007; 12(1): 29 - 31. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Riviello Jr Pharmacology Review: Drug Therapy for Neonatal Seizures: Part 1 NeoReviews, May 1, 2004; 5(5): e215 - e220. [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Manno New Management Strategies in the Treatment of Status Epilepticus Mayo Clin. Proc., April 1, 2003; 78(4): 508 - 518. [Abstract] [PDF]
|
|
|
|
|
|
J. G. Burneo, G. L. Barkley, T. J. O'Brien, and F. J. Vajda Prospective study of local cutaneous reactions in patients receiving IV phenytoin Neurology, April 9, 2002; 58(7): 1134 - 1134. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Edwards and V. Bosek Extravasation Injury of the Upper Extremity by Intravenous Phenytoin Anesth. Analg., March 1, 2002; 94(3): 672 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. O'Brien, F. M. Meara, H. Matthews, and F. J. Vajda Prospective study of local cutaneous reactions in patients receiving IV phenytoin Neurology, October 23, 2001; 57(8): 1508 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yoshikawa, T. Abe, and Y. Oda Purple Glove Syndrome Caused by Oral Administration of Phenytoin J Child Neurol, November 1, 2000; 15(11): 762 - 762. [Abstract] [PDF]
|
|
|
|
 |
|
 P. D. Meek, S. N. Davis, D. M. Collins, B. E. Gidal, P. A. Rutecki, A. H. Burstein, J. H. Fischer, I. E. Leppik, R. E. Ramsay, and for the Panel on Nonemergency Use of Parenteral Ph Guidelines for Nonemergency Use of Parenteral Phenytoin Products: Proceedings of an Expert Panel Consensus Process Arch Intern Med, December 13, 1999; 159(22): 2639 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Coplin, D. H. Rhoney, E. A. Lyons, K. R. Murry, T. J. O'Brien, G. D. Cascino, E. L. So, D. R. Hanna Rochester MN, and T. R. Browne Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin Neurology, October 22, 1999; 53(7): 1611 - 1611. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
